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Abstract 
Plasmodium falciparum has developed resistance to almost every class of antimalarial compounds.  As 
a result of this, the World Health Organization has recommended artemisinin-based combination 
therapy as first line treatment for P. falciparum malaria.  There is however need for the continuous 
monitoring of the efficacy of these antimalarials in order to provide timely information on trends of 
the emergence of resistant strains.  We assessed the therapeutic efficacy of oral artesunate –
amodiaquine and artemether-lumefantrine combinations in the treatment of uncomplicated P. 
falciparum malaria in four District Hospitals in Sierra Leone.  A total of 320 children under five years 
partiiccipated in the study sites (Kenema, Rokupa, Bo and Makeni). Oral Artesunate-amodiaquine 
combination was administered to participants in Kenema and Rokupa whilst Artemether-
lumefantrine combination was administered to participants in Bo and Makeni.  The new WHO 
Protocol for recruitment of participants in therapeutic efficacy trials in high transmission zones was 
adopted for the study with filter paper blood samples taken from each participant on days 0 and 28 to 
distinguish between treatment failure and new infection.  When uncorrected for PCR analysis, 96% 
(95% CI: 902 – 989) and 100% (95% CI:63.1 – 100) responses were obtained in Kenema and Bo 
respectively with Artesunate-amodiaquine combination whilst 94.3% (CI 95 : 88.1 – 979) and 100% 
(95% CI: 96.5 – 100) were obtained with Artemether-lumefantrine combination  in Bo and Makeni  
respectively.  When corrected for PCR on the other hand, a 100% (95% CI) Adequate Clinical and 
Parasitological Response was obtained for the two drugs in all four study sites.  Results from this 
study indicate that both Artesunate-amodiaquine and Artemether-lumefantrine combinations remain 
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Introduction 
Malaria remains a major cause of morbidity 
and mortality and is estimated to cause 
881,000 deaths globally per year. Sub-Saharan 
Africa is disproportionately affected, suffering 
91% of global malaria deaths with 88% 
occu
rring 




Recent reports however indicate that in almost 
40% of the world’s malaria endemic countries 
reported cases have dropped by half over the 
last decade (Johnson et al 2010). Plasmodium 
falciparum, which causes the most life-




every class of antimalarial compound (WHO 
2010), as a result of which the 
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 World Health Organization has recommended 
artemisinin-based combination therapy (ACT)  
as first-line treatment of P. falciparum malaria.  
ACT is the combination of artemisinin or an 
artemisinin derivative (artesunate, artemether, 
dehydraartemisinin) and a partner drug 
(amodiaquine, mefloquine, piperaquine, 
lumifantrine, sulphadoxine, pyremethamine) 
having a markedly longer half life in the blood 
stream than artemisinin. 
 
Hence, the rationale for ACT is that the 
artemisinin precipitously reduces the 
parasiteamia, and the less potent but longer-
acting partner drug kills any residual parasites 
over 1 – 2 weeks (Fairhurst et al 2012).  Recent 
reports suggest an impaired parasite response 
to artemisinin monotherapy in the Cambodia-
Thailand border region (Dondorp et al 2009; 
Anderson et al 2010).  Here in Sierra Leone 
treatment failures with artemisinin 
monotherapy have also been reported  (Sahr et 
al 2001). 
 
There is no available data on the efficacy of 
ACTs in Sierra Leone although limited data 
does suggest that failed treatment to these 
drugs is rare (Sahr et al 2009).   No nationwide 
survey has been attempted to monitor the 
efficacy of the ACTs in Sierra Leone since their 
introduction in 2008.  The introduction of a 
new antimalarial drug requires continuous 
monitoring in order to provide timely 
information on the emergence of resistant 
strains.  The objective of this study was to 
assess the therapeutic efficacy of oral 
Artesunate-amodiaquine and oral Artemether 
– lumifantrine combination therapies in the 
treatment of uncomplicated P. falciparum 
malaria and corrected for PCR analysis in 
children under 5 years in four (4) District 
hospitals in Sierra Leone. 
 
Patients and Methods  
a. Study design 
This was a randomized efficacy study of oral 
artesunate-amodiaquine and oral artemether – 
lumifantrine combination therapies for the 
treatment of uncomplicated P. falciparum 
malaria in children under 5 years, conducted 
according to the principles of Good Clinical 
Practice.  Study sites were randomly assigned 
to 1 of 2 study drugs: (1) Oral Artesunate – 
amodiaquine combination therapy or (2) Oral 
Artemether – lumifantrine combination 
therapy, administered according to the 
recommendation of the World Health 
Organization.   
The study was approved by the Ethics and 
Research Committee of the Ministry of Health 
and Sanitation.  
 
b. Data collection 
Data was collected in four Government 
Hospitals:  Kenema, Rokupa, Bo and Makeni.  
All four Hospitals are supervised by Medical 
Doctors with established Under-five Clinics 
and Laboratories.  Only children below five 
years were enrolled in the study.  The new 
WHO Protocol (WHO 2008) for recruitment of 
participants in therapeutic efficacy trials in 
high transmission zones was adopted.  Filter 
Paper blood were taken from each participant 
on Days 0 and 28 for PCR analysis where 
indicated to distinguish between 
parasitological failure and new infection.    
Inclusion criteria used in the study were: 
children below 5 years, axillary temperature > 
37.50C, mono-infection with Plasmodium 
falciparum, parasitaemia > 1000 parasites/µl 
of blood, and informed consent from 
accompanying parents or guardians. 
Participants with severe or complicated 
malaria according to the WHO classification 
(WHO 1996) were excluded from the study 
and treated with parenteral artemisinin.   The 
two study drugs were provided by WHO and 
passed the general counterfeit test of the 
Pharmacy Board of the Ministry of Health and 
Sanitation. 
Both artesunate-amodiaquine and artemether 
– lumifantrine were administered orally under 
the direct supervision of a nurse.   Participants 
were followed-up on Days 1, 2, 3, 7, 14, 21 and 
28 during which their general conditions were 
assessed and blood smears prepared for the 
demonstration and quantification of 
Plasmodium falciparum parasitaemia.   Axillary 
temperature was recorded for each participant 
on all follow-up days and the response to 
treatment recorded according to the WHO 
recommendation (WHO 1996): Adequate 
Clinical and Parasitological Response (ACPR), 
Early Treatment Failure (ETF) and Late 
Treatment Failure (LTF).   Briefly, ACPR was 
defined as absence of parasitaemia on day 14 
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irrespective of axillary temperature < 37.50C 
and irrespective of parasitaemia without 
previously meeting any of the criteria of ETF.   
Therapeutic response was classified as ETF if 
the subject developed one of the following 
conditions during the first three days of 
follow-up: 
a. Axillary temperature ≥ 37.50C on Day 2 
with parasitaemia greater than that on Day 
0. 
b. Axillary temperature ≥37.50C on Day 3 in 
the presence of parasitaemia. 
c. Parasitaemia on Day 3 ≥ 25% of count on 
Day 0. 
Therapeutic response was classified as LTF if a 
participant’s axillary temperature was ≥ 37.5% 
in the presence of parasitaemia on any day 
from Day 4 to Day 14 without previously 
meeting the criteria of ETF. 
 
Ethical Clearance 
Ethical clearance for the conduct of the study 
was obtained from the Ethics and Research 




A total of 320 children below 5 years were 
enrolled in the study.  Of these, 101 were 
from Kenema, 8 from Rokupa, 106 from Bo 
and 105 from Makeni.   Artesunate-
amodiaquine combined therapy was 
administered to participants in Kenema and 
Rokupa, while artemether – lumifantrine 
combined therapy was administered to 
participants in Bo and Makeni.  Table I 
summarizes the therapeutic efficacy of the 
two study drugs amongst the 320 participants 
from the four study sites without PCR 
analysis of the filter paper blood to 
distinguish between true parasitological 
failure and re-infection. From Table I, 96% 
and 100% Adequate Clinical and 
Parasitological Responses were observed with 
Artesunate-amodiaquine combined therapy in 
Kenema and Rokupa respectively (95% CI).   
For Artemether-lumifantrine combined 
therapy on the other hand, 94.3% and 100% 
Clinical and Parasitological Responses were 
observed in Bo and Makeni respectively 
(95% CI).  After PCR analysis of the filter 
blood samples of the participants with 
apparent Clinical and Parasitological failure 
in Kenema for artesunate-amodiaquine and 
Bo for artemether-lumifantrine combined 
therapies, a 100% Adequate Clinical and 
Parasitological Response was obtained for the 
two study drugs in the four study sites (Table 
II). 
 
Table 1.  Therapeutic efficacy of artesunate + amodiaquine in two sites and 
artemether+lumefantrine in two sites, Sierra Leone.    
 
PCR  uncorrected responses 
.
 
Treatment outcome Artesunate + amodiaquine Artemether + lumefantrine 
Kenema (n = 
101) 
Rokupa (n = 8) Bo (n = 106) Makeni ( n = 
105) 
% Early Treatment Failure (95% CI) 0.0 (0.0-3.6) 0.0 (0.0 – 36.9) 0.0 (0.0 – 3.4) 0.0 (0.0 – 3.5) 
% Late Treatment Failure (95% CI) 1.0 (0.0 – 5.4) 0.0 (0.0 – 36.9) 0.9 (0.0 – 5.1) 0.0 (0.0 – 3.5) 
% Late Parasitological Failure (95% 
CI) 
3.0 (0.6 – 8.4) 0.0 (0.0 – 36.9) 4.7 ( 1.5 – 10.7) 0.0 (0.0 – 3.5) 
% Adequate Clinical & Parasitological 
Response (95% CI) 
96.0 (90.2 – 
98.9) 
100 (63.1 – 100) 94.4 (88.1 – 97.9) 100 (96.5 – 100) 
Kaplan-Meier Cumulative Treatment 
Failure Rate 
0.0 0.0 5.6 (2.6 – 12.1) 0.0 
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Table 2.  Therapeutic efficacy of artesunate+amodiaquine in four sites and 
artemether+lumefantrine in four sites, Sierral Leone. 





















Child mortality from P. falciparum malaria 
increased significantly in the 1980s when 
chloroquine-resistant parasites arrived in Sub-
Saharan Africa (Trape 2001; Dondrop et al 
2010).  As the parasite developed resistance to 
more antimalarial drugs, the World Health 
Organization recommended ACTs as first-line 
treatment for uncomplicated P. falciparum 
malaria.  Although the most common ACTs are 
Artemether-mefloquine and Artemether-
lumifantrine (WHO 2006), the Ministry of 
Health and Sanitation in Sierra Leone 
recommend Oral Artesunate-amodiaqine and 
oral artemether-lumefantrine for the 
treatment of uncomplicated P. falciparum 
malaria. 
 
When the results are not corrected for with 
PCR analysis, a 3% and 4.7% Late 
Parasitological failures were observed in 
Kenema and Bo respectively.  With PCR 
corrected responses on the other hand, results 
suggest that both oral Artesunate-amodiaquine 
and oral artemether-lumefantrine combination 
therapies are highly efficacious in the 
treatment of uncomplicated P. falciparum 
malaria as evidenced by the 100% ACPR in all 
four study sites. 
Although there are no available reports on 
treatment failures with ACTs in Sierra Leone, a 
number of research groups in South –East Asia 
have started detecting the first signs of 
artemisinin resistant which may threaten to 
compromise the efficacy of ACTs (Fairhurst 
2012).  Recent clinical and molecular studies 
suggest the emergence of ACT-resistant 
Plasmodium falciparum in the Cambodia-
Thailand border area, were the standard ACT 
is Artesunate-mefloquine combination therapy 
(Wongsrichanalia et al 2000).  They suggested 
that the treatment failures reported might be 
due to mefloquine used as monotherapy in the 
treatment of P. falciparum malaria long before 
the introduction of ACTs. 
Sahr et al (2001) reported 4 cases of apparent 
treatment failure with Aretsunate use as 
monotherapy. Using the WHO criteria for the 
classification of treatment outcome with 
antimalarial drugs, all four treatment failures 
were reported as ETFs.  In a therapeutic 
efficacy study conducted in Ghana by Abuaku 
et al 2012 to evaluate Artemether-
lumefantrine in the treatment of 
uncomplicated malaria in children under 5 







(n=106) Makeni (n=105) 
% Early Treatment failure 
(95% CI) 
0.0 (0.0-3.7) 0.0 (0.0-36.9) 0.0 (0.0-3.6) 0.0 (0.0-3.5) 
% Late Clinical Failure(95% 
CI) 






0.0 (0.0-3.7) 0.0 (0.0-36.9) 
0.0 (0.0-3.6) 
0.0 (0.0-3.5) 











Treatment Failure Rate 
0.0 0.0 0.0 0.0 
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years in three ecological zones, they reported 
an overall pre-corrected cure rate of 95.4% 
(95% CI: 90.3 – 98.0).  These results are similar 
to our PCR uncorrected response of 96.0% 
(95% CI) and 94.3% (95% CI) obtained in 
Kenema and Bo respectively.  They concluded 
from their study that Artemether-lumefantrine 
remains efficacious in Ghana for the treatment 
of uncomplicated malaria.   Post corrected PCR 
cure rates in our study demonstrated a 100% 
ACPR (95% CI) in all four study sites on Day 
28.  This shows that both oral Artesunate-
amodiaquine and artemether-lumefantrine are 
highly efficacious in the treatment of 
uncomplicated P. falciparum malaria in Sierra 
Leone and emergences of resistant strains of 
the parasite to the two drugs are yet to appear. 
It is therefore recommended that the Ministry 
of Health and Sanitation undertakes 
continuous monitoring of the efficacy of these 
drugs so that timely information on the 
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